Attenuated Bordetella pertussis Protects against Highly Pathogenic Influenza A Viruses by Dampening the Cytokine Storm

Abstract

The threat of a pandemic spread of highly virulent influenza A viruses currently represents a top global public health problem. Mass vaccination remains the most effective way to combat influenza virus. However, current vaccination strategies face the challenge to meet the demands in a pandemic situation. In a mouse model of severe influenza virus-induced pneumonitis, we observed that prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained protection against lethal challenge with two different influenza A virus subtypes. In contrast to most cross-protective effects reported so far, the protective window offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting a unique mechanism(s) involved in the protection. No significant differences in viral loads were observed between BPZE1-treated and control mice, indicating that the cross-protective mechanism(s) does not directly target the viral particles and/or infected cells. This was further confirmed by the absence of cross-reactive antibodies and T cells in serum transfer and in vitro restimulation experiments, respectively. Instead, compared to infected control mice, BPZE1-treated animals displayed markedly reduced lung inflammation and tissue damage, decreased neutrophil infiltration, and strong suppression of the production of major proinflammatory mediators in their bronchoalveolar fluids (BALFs). Our findings thus indicate that protection against influenza virus-induced severe pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated inflammation. Furthermore, nasal treatment with live attenuated B. pertussis offers a potential alternative to conventional approaches in the fight against one of the most frightening current global public health threats.

Inducible Major Vault Protein Plays a Pivotal Role in Double-Stranded RNA– or Virus-Induced Proinflammatory Response

“…The homogenates were centrifuged at 12,000 3 g for 20 min to remove cell debris and the supernatants were stored at 280˚C until assay. Lung viral titers were determined by a modified TCID 50 assay reported by the World Health Organization (38). Briefly, confluent monolayers of Madin-Darby canine kidney cells on 96-well plates were incubated, in octuplicate, with 100 ml 10-fold serially diluted lung homogenates.…”

Temporary CXCR3 and CCR5 Antagonism Following Vaccination Enhances Memory CD8 T Cell Immune Responses

“…(25) Briefly, 90% confluent Madin-Darby canine kidney (MDCK) cells in 96-well plates were inoculated with 100 μL of 10-fold serially diluted lung homogenates. Plates were incubated at 35°C in a humidified incubator (5% CO 2 ) for 3 d. TCID50 was determined by a reduction in cytopathic effect (CPE) of 50%, and the log TCID50/lung was derived.…”

Natural Killer Cells Are Involved in Acute Lung Immune Injury Caused by Respiratory Syncytial Virus Infection

“…Bronchoalveolar lavage fluids (BALF) were gathered as previously described (20). In brief, sterile phosphatebuffered saline (PBS) (1 ml) was injected into the lungs of sacrificed mice, a lavage step was performed once, and then BALF samples were centrifuged at 350 ϫ g for 5 min (4°C) and the supernatants were collected and kept at Ϫ80°C until required.…”